Stéphane Léonce
Research Subjects
Stéphane Léonce has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Bruno Pfeiffer
5 shared publications- François Tillequin
Laboratoire de Pharmacognosie, UMR 8638, Faculté des Sciences Pharmaceutiques et Biologiques, Université René-Descartes, 4, Avenue de l'Observatoire, 75270 Paris Cedex 06, France
4 shared publications Alain Pierre
Institut de Recherche Servier, Division de Cancérologie Expérimentale, 11 Rue des Moulineaux, 92150, Suresnes, France
3 shared publicationsAlain Pierré
3 shared publicationsGhanem Atassi
Institut de Recherches Servier, Suresnes, France (S.L., V.P., S.L., D.P., G.A., J.A.H., A.P.); 2Laboratoire de Pharmacognosie de l'Université René Descartes, Paris, France (F.T., S.M., M.K.); 3ADIR et Cie, Courbevoie, France (B.P.)
3 shared publications- Sylvie Michel
Faculty of Pharmacy, Faculty of Health Paris Cité University, CNRS, Therapeutic Targets and Drug Design Laboratory, UMR 8038 Paris France
3 shared publications
Latest Publications
- 1 August 2011
- Published by Elsevier in Tetrahedron Letters
- Vol. 52 (34) , 4426-4429
Tröger’s bases in the acronycine, benzo[a]acronycine, and benzo[b]acronycine series
- 1 August 2011
- Published by Elsevier in Tetrahedron Letters
- Vol. 52 (34) , 4426-4429
Tröger’s bases in the acronycine, benzo[a]acronycine, and benzo[b]acronycine series
- 1 May 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (5) , 1861-1873
Synthesis and cytotoxic activity of benzo[a]acronycine and benzo[b]acronycine substituted on the A ring
- 1 May 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (5) , 1861-1873
Synthesis and cytotoxic activity of benzo[a]acronycine and benzo[b]acronycine substituted on the A ring
- 31 January 2008
- Published by Elsevier in Phytochemistry
- Vol. 69 (2) , 533-540
Cytotoxic turrianes of Kermadecia elliptica from the New Caledonian rainforest
- 31 January 2008
- Published by Elsevier in Phytochemistry
- Vol. 69 (2) , 533-540
Cytotoxic turrianes of Kermadecia elliptica from the New Caledonian rainforest
- Open Access
- 1 April 2003
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 18 (2) , 167-174
Synthesis and Cytotoxic Evaluation of Novel Thiazolocarbazoles. Part II1
Novel thiazolocarbazole derivatives have been synthesized via the corresponding imino-1,2,3-dithiazoles. In vitro antitumor activity of these polyheterocyclic compounds was studied.
- 1 April 2003
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 18 (2) , 167-174
Open AccessSynthesis and Cytotoxic Evaluation of Novel Thiazolocarbazoles. Part II1
Novel thiazolocarbazole derivatives have been synthesized via the corresponding imino-1,2,3-dithiazoles. In vitro antitumor activity of these polyheterocyclic compounds was studied.
- 1 January 2003
- Vol. 13 (4) , 191-7
Synthesis of 6-dialkylaminoalkylamino pyrano[2,3-c]acridones and benzo[b]pyrano[3,2-h]acridones: soluble acronycine analogues with increased cytotoxic activity.
The novel 6-dialkylaminoalkylamino-3,3,12-trimethyl-3,12-dihydro-7H-pyrano[2,3-c]acridine-7-ones 5-11 and their benzo [b]pyrano[2,3-h]acridine-7-one counterparts 12-18 were prepared by treatment of acronycine (1) or benzo[b]acronycine (4) with an excess of the appropriate dialkylaminoalkylamine. In both series, the introduction of a dialkylaminoalkylamino side chain at position 6 resulted in a significant increase of the cytotoxic activity against L1210 cells when compared with the parent compounds bearing a methoxy group, accompanied with an increased potency to arrest cells in the G2 + M phases of the cell cycle.
- 1 January 2003
- Vol. 13 (4) , 191-7
Synthesis of 6-dialkylaminoalkylamino pyrano[2,3-c]acridones and benzo[b]pyrano[3,2-h]acridones: soluble acronycine analogues with increased cytotoxic activity.
The novel 6-dialkylaminoalkylamino-3,3,12-trimethyl-3,12-dihydro-7H-pyrano[2,3-c]acridine-7-ones 5-11 and their benzo [b]pyrano[2,3-h]acridine-7-one counterparts 12-18 were prepared by treatment of acronycine (1) or benzo[b]acronycine (4) with an excess of the appropriate dialkylaminoalkylamine. In both series, the introduction of a dialkylaminoalkylamino side chain at position 6 resulted in a significant increase of the cytotoxic activity against L1210 cells when compared with the parent compounds bearing a methoxy group, accompanied with an increased potency to arrest cells in the G2 + M phases of the cell cycle.
- 1 December 2001
- Published by Elsevier in Molecular Pharmacology
- Vol. 60 (6) , 1383-1391
Induction of Cyclin E and Inhibition of DNA Synthesis by the Novel Acronycine Derivative S23906-1 Precede the Irreversible Arrest of Tumor Cells in S Phase Leading to Apoptosis
S23906-1 is a diester derivative of 1,2-dihydrobenzo[b]acronycine with an unknown mechanism of action. This cytotoxic compound was 20-fold more potent than acronycine in inhibiting the proliferation of six tumor cell lines. Using a clonogenic assay of cell survival, the HT29 human colon carcinoma cell line was 100-fold more sensitive to S23906-1 than acronycine. Cell cycle analysis, by flow cytometry, showed thatS23906-1 induced a partially reversible arrest of HT29 cells in G2+M at 1 μM and below and an irreversible arrest in S phase at 2.5 μM and above. These cell cycle effects were followed by cell death through apoptosis, quantified by annexin-V labeling. Inhibition of DNA synthesis was observed by complete prevention of bromodeoxyuridine (BrdU) incorporation after only 4 h of incubation with 5 μM S23906-1. Interestingly, under the same experimental conditions, a significant increase of cyclin E protein level was observed without any modification of cyclins D1, D2, D3, or A. This overexpressed cyclin E protein was not complexed with Cdk2, as shown by western blotting for Cdk2 in immunoprecipitates of cyclin E. Similar inhibition of BrdU incorporation and elevation of cyclin E protein were observed after treatment with cytosine arabinoside, which reversibly inhibited progression into S phase, but not after DNA damage induced by cisplatin. S23906-1 thus has a novel mechanism of action. A cell line resistant to S23906-1 showed that overexpression of cyclin E was implicated in the novel cytotoxic activity of this compound.
- 1 December 2001
- Published by Elsevier in Molecular Pharmacology
- Vol. 60 (6) , 1383-1391
Induction of Cyclin E and Inhibition of DNA Synthesis by the Novel Acronycine Derivative S23906-1 Precede the Irreversible Arrest of Tumor Cells in S Phase Leading to Apoptosis
S23906-1 is a diester derivative of 1,2-dihydrobenzo[b]acronycine with an unknown mechanism of action. This cytotoxic compound was 20-fold more potent than acronycine in inhibiting the proliferation of six tumor cell lines. Using a clonogenic assay of cell survival, the HT29 human colon carcinoma cell line was 100-fold more sensitive to S23906-1 than acronycine. Cell cycle analysis, by flow cytometry, showed thatS23906-1 induced a partially reversible arrest of HT29 cells in G2+M at 1 μM and below and an irreversible arrest in S phase at 2.5 μM and above. These cell cycle effects were followed by cell death through apoptosis, quantified by annexin-V labeling. Inhibition of DNA synthesis was observed by complete prevention of bromodeoxyuridine (BrdU) incorporation after only 4 h of incubation with 5 μM S23906-1. Interestingly, under the same experimental conditions, a significant increase of cyclin E protein level was observed without any modification of cyclins D1, D2, D3, or A. This overexpressed cyclin E protein was not complexed with Cdk2, as shown by western blotting for Cdk2 in immunoprecipitates of cyclin E. Similar inhibition of BrdU incorporation and elevation of cyclin E protein were observed after treatment with cytosine arabinoside, which reversibly inhibited progression into S phase, but not after DNA damage induced by cisplatin. S23906-1 thus has a novel mechanism of action. A cell line resistant to S23906-1 showed that overexpression of cyclin E was implicated in the novel cytotoxic activity of this compound.
- 1 January 1998
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 46 (1) , 34-41
Synthesis and Cytotoxic Activity of Pyranophenanthridine Analogues of Fagaronine and Acronycine.
Condensation of 5-amino, 6-amino, 7-amino and 8-amino-2, 2-dimethyl-2H-chromenes with either 6-bromo-veratraldehyde or 6-chloropiperonal afforded the corresponding Schiff bases, which were subsequently reduced to the corresponding benzylchromenylamines 30-33 and 36-39. Lithium diisopropylamide-mediated cyclization of those amines, followed by spontaneous air oxidation, afforded pyranophenanthridines 3-14. The cytotoxicity of compounds 3-14 was evaluated against L1210 and HT29 cell lines. 9, 9-Dimethyl-9H-pyrano[3, 2-b]phenanthridines appear to be the most promising compounds of the series, since both the dimethoxy derivative 11 and the methylenedioxy derivative 12 exhibit significant cytotoxic activity. Compound 12 was the most active and induced a massive accumulation of cells in G2+M phases, suggesting that the cytotoxicity is due to a perturbation of the integrity or function of DNA.
- 1 January 1998
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 46 (1) , 34-41
Synthesis and Cytotoxic Activity of Pyranophenanthridine Analogues of Fagaronine and Acronycine.
Condensation of 5-amino, 6-amino, 7-amino and 8-amino-2, 2-dimethyl-2H-chromenes with either 6-bromo-veratraldehyde or 6-chloropiperonal afforded the corresponding Schiff bases, which were subsequently reduced to the corresponding benzylchromenylamines 30-33 and 36-39. Lithium diisopropylamide-mediated cyclization of those amines, followed by spontaneous air oxidation, afforded pyranophenanthridines 3-14. The cytotoxicity of compounds 3-14 was evaluated against L1210 and HT29 cell lines. 9, 9-Dimethyl-9H-pyrano[3, 2-b]phenanthridines appear to be the most promising compounds of the series, since both the dimethoxy derivative 11 and the methylenedioxy derivative 12 exhibit significant cytotoxic activity. Compound 12 was the most active and induced a massive accumulation of cells in G2+M phases, suggesting that the cytotoxicity is due to a perturbation of the integrity or function of DNA.
- 1 January 1996
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 44 (11) , 2169-2172
Synthesis and Biological Evaluation of 6-(9-Hydroxy-5-methyl(and 5,6-Dimethyl)-6H-pyrido(4,3-b)carbazol-1-yl)picolinic Amides as New Olivacine Derivatives.
Starting from 2-(6-methoxy-1-methylcarbazol-2-yl)ethylamine and diethyl-2,6-pyridine dicarboxylate, the title compounds were obtained through five or six steps. The new compounds retained significant cytotoxicity towards various tumor cell lines, but in vivo studies on murine P388 leukemia, B16 melanoma and Lewis lung carcinoma showed a lowered antitumor activity with respect to that of the related olivacine lead compound 1.
- 1 January 1996
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 44 (11) , 2169-2172
Synthesis and Biological Evaluation of 6-(9-Hydroxy-5-methyl(and 5,6-Dimethyl)-6H-pyrido(4,3-b)carbazol-1-yl)picolinic Amides as New Olivacine Derivatives.
Starting from 2-(6-methoxy-1-methylcarbazol-2-yl)ethylamine and diethyl-2,6-pyridine dicarboxylate, the title compounds were obtained through five or six steps. The new compounds retained significant cytotoxicity towards various tumor cell lines, but in vivo studies on murine P388 leukemia, B16 melanoma and Lewis lung carcinoma showed a lowered antitumor activity with respect to that of the related olivacine lead compound 1.